Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2016 - 2022)

Enanta Pharmaceuticals filings provide 11 years of Other Non Operating Income readings, the most recent being $393000.0 for Q2 2022.

  • On a quarterly basis, Other Non Operating Income fell 10.48% to $393000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was -$782000.0, a 78.64% increase, with the full-year FY2021 number at -$27000.0, down 118.12% from a year prior.
  • Other Non Operating Income hit $393000.0 in Q2 2022 for Enanta Pharmaceuticals, up from $255000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.4 million in Q2 2019 to a low of -$5.3 million in Q3 2020.
  • Median Other Non Operating Income over the past 5 years was $393000.0 (2022), compared with a mean of $222800.0.
  • Biggest five-year swings in Other Non Operating Income: crashed 115.15% in 2018 and later skyrocketed 24050.0% in 2019.
  • Enanta Pharmaceuticals' Other Non Operating Income stood at -$100000.0 in 2018, then skyrocketed by 2176.0% to $2.1 million in 2019, then crashed by 67.39% to $677000.0 in 2020, then tumbled by 61.89% to $258000.0 in 2021, then surged by 52.33% to $393000.0 in 2022.
  • The last three reported values for Other Non Operating Income were $393000.0 (Q2 2022), $255000.0 (Q1 2022), and $258000.0 (Q4 2021) per Business Quant data.